| scholarly article | Q13442814 |
| P2093 | author name string | Carolyn L Smith | |
| Shuang Liu | |||
| Sang Jun Han | |||
| P2860 | cites work | LXR, a nuclear receptor that defines a distinct retinoid response pathway | Q24317347 |
| Histone H4K20/H3K9 demethylase PHF8 regulates zebrafish brain and craniofacial development | Q24338532 | ||
| The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily | Q24530578 | ||
| Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA | Q24655111 | ||
| Structural insights into the mode of action of a pure antiestrogen | Q27630646 | ||
| Structural basis for a molecular allosteric control mechanism of cofactor binding to nuclear receptors | Q27677404 | ||
| The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements | Q27731441 | ||
| Molecular basis of agonism and antagonism in the oestrogen receptor | Q27746278 | ||
| The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen | Q27766417 | ||
| A signature motif in transcriptional co-activators mediates binding to nuclear receptors | Q27860938 | ||
| Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA | Q28115652 | ||
| Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1 | Q28260929 | ||
| International Union of Pharmacology. LXIII. Retinoid X receptors | Q28276158 | ||
| Unique response pathways are established by allosteric interactions among nuclear hormone receptors | Q28301832 | ||
| Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors | Q28326688 | ||
| The RXR heterodimers and orphan receptors | Q29547867 | ||
| Estrogen receptors: how do they signal and what are their targets | Q29617958 | ||
| Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics | Q30418832 | ||
| Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial | Q30448633 | ||
| The human estrogen receptor alpha dimer binds a single SRC-1 coactivator molecule with an affinity dictated by agonist structure. | Q31937889 | ||
| Whole-genome cartography of estrogen receptor alpha binding sites | Q33286418 | ||
| Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex | Q33957429 | ||
| Estrogen receptor interaction with estrogen response elements | Q34307898 | ||
| Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions | Q34727705 | ||
| DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex | Q34927801 | ||
| Expanding the paradigm for estrogen receptor binding and transcriptional activation | Q35001279 | ||
| Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes | Q36065502 | ||
| Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor alpha (RAR alpha)-, RAR beta-, or RAR gamma-selective ligand in combination with a retinoid X receptor-specific | Q36556052 | ||
| Estrogens in the breast tissue: a systematic review | Q36840495 | ||
| Proteasome-dependent degradation of the human estrogen receptor | Q37160826 | ||
| Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator | Q37324395 | ||
| Breast cancer, estrogen receptor and ligands | Q37410993 | ||
| Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms | Q37768158 | ||
| Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE) | Q37808639 | ||
| Modulation of RXR function through ligand design | Q37868350 | ||
| The different roles of ER subtypes in cancer biology and therapy | Q37903655 | ||
| Analysis of mechanisms that determine dominant negative estrogen receptor effectiveness | Q38287686 | ||
| Dimerizing the estrogen receptor DNA binding domain enhances binding to estrogen response elements | Q38342109 | ||
| Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens | Q39774441 | ||
| 9-cis retinoic acid signaling: changing partners causes some excitement | Q40468056 | ||
| The relative contribution exerted by AF-1 and AF-2 transactivation functions in estrogen receptor alpha transcriptional activity depends upon the differentiation stage of the cell | Q40567948 | ||
| Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators | Q41007539 | ||
| Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen | Q41222398 | ||
| Polarity-specific activities of retinoic acid receptors determined by a co-repressor. | Q41284148 | ||
| Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding | Q41436527 | ||
| Activation of specific RXR heterodimers by an antagonist of RXR homodimers | Q42553589 | ||
| Co-regulator recruitment and the mechanism of retinoic acid receptor synergy | Q43863364 | ||
| Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate | Q44232745 | ||
| Structural determinants of allosteric ligand activation in RXR heterodimers. | Q44796708 | ||
| Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. | Q45918585 | ||
| DNA recognition by the oestrogen receptor: from solution to the crystal | Q47964761 | ||
| Three amino acids of the oestrogen receptor are essential to its ability to distinguish an oestrogen from a glucocorticoid-responsive element | Q59070120 | ||
| A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity | Q77387784 | ||
| Tamoxifen in the treatment of breast cancer | Q77598704 | ||
| The vitamin D receptor binds in a transcriptionally inactive form and without a defined polarity on a retinoic acid response element | Q77774307 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 1066-1077 | |
| P577 | publication date | 2013-03-05 | |
| P1433 | published in | Molecular Pharmacology | Q1943386 |
| P1476 | title | Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes | |
| P478 | volume | 83 |
| Q30409045 | Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes |
| Q52342343 | Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen. |
| Q38307019 | Emerging hormonal treatments for menopausal symptoms |
| Q28533967 | Evaluation of estrogenic potential of flavonoids using a recombinant yeast strain and MCF7/BUS cell proliferation assay |
| Q36917897 | Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones. |
| Q34490225 | Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast |
| Q36432425 | The Dual Estrogen Receptor α Inhibitory Effects of the Tissue-Selective Estrogen Complex for Endometrial and Breast Safety |
| Q38993271 | The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms |
| Q53837780 | Tissue selective estrogen complex (TSEC): a review. |
Search more.